Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the need for increased lung cancer screening among patients who have no tobacco use history.
We currently do not have a system in place for screening never-smokers for lung cancer, explained Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon.
Transcript
Is enough being done to identify patients who should be screened for lung cancer, including never-smokers?
We know that screening patients for lung cancers decreases the number of patients being diagnosed with lung cancer each year. The problem is that the [National Lung Screening Trial] data is not always generalizable to all patients. You mentioned the never-smokers. It's a really good question. We don't have a mechanism for screening never-smokers. Just in 2021, we have decreased the number of pack-years required from 30 pack-years to 20 pack-years and decreased the age from 55 to 50 for patients to make them eligible for screening. And so those are steps in the right direction. But we'll never get to never-smokers if we're just looking for patients that have a tobacco screening history. In parts of the world such as Asia, 50% of lung cancer patients will be never-smokers. And so that shows us that our current ways of selecting patients (ie, their tobacco exposure history) are neither sufficient nor far-reaching enough to really be identifying those patients most at risk because they're not thinking about it.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More